Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Silo Pharma Inc (NQ: SILO ) 1.050 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Silo Pharma Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation January 10, 2023 From Silo Pharma, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Friday January 06, 2023 During Friday's trading, 71 companies set new 52-week lows. Via Benzinga Silo Pharma Stock Surges After Positive Study Results From Arthritis Study December 30, 2022 Via Benzinga Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 03, 2023 Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. Via Benzinga InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study January 03, 2023 Via Investor Brand Network What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways January 03, 2023 What a year for psychedelics! Via Benzinga Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket January 03, 2023 Gainers Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session January 02, 2023 Via Benzinga Nasdaq Falls 100 Points; Dermata Therapeutics Shares Surge December 30, 2022 U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 100 points on Friday. Via Benzinga Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session December 30, 2022 Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... Via Benzinga Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis December 30, 2022 Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics Via Spotlight Growth US Stocks Open Lower; Dow Drops 250 Points December 30, 2022 U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Friday. Via Benzinga Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030 December 30, 2022 EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END Via FinancialNewsMedia Silo Pharma Announces Positive Study Results of SPU December 30, 2022 21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December... Via FinancialNewsMedia Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis December 30, 2022 From Silo Pharma, Inc. Via GlobeNewswire InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter December 01, 2022 Via Investor Brand Network Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine December 01, 2022 From Silo Pharma, Inc. Via GlobeNewswire PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue November 21, 2022 Via Investor Brand Network Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue November 21, 2022 From Silo Pharma, Inc. Via GlobeNewswire 7 Millionaire-Maker Stocks You Will Regret Not Buying This Year November 17, 2022 With the market shifting toward a deflationary stance, investors should target these robust millionaire-maker stocks to buy. Via InvestorPlace Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial November 11, 2022 Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu Via Benzinga PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation November 11, 2022 Via Investor Brand Network Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation November 11, 2022 From Silo Pharma, Inc. Via GlobeNewswire New Psychedelic Journal to Focus on Publishing Psychedelic Research November 07, 2022 Via Investor Brand Network Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease November 04, 2022 Via Investor Brand Network PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation November 03, 2022 Via Investor Brand Network Microscopy Provides Insights on Psychedelics Action Inside Neuropathways October 28, 2022 Via Investor Brand Network PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector October 26, 2022 Via Investor Brand Network Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference October 26, 2022 From Silo Pharma, Inc. Via GlobeNewswire PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions October 24, 2022 Via Investor Brand Network < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.